Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
There are 38.4 million people with diabetes in the United States
Subscribe To Our Newsletter & Stay Updated